Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: A prospective cohort study

The Lancet Neurology

Volumn 14, Issue 8, 2015, Pages 804-813

  Yau, Wai Ying Wendy ^a   Tudorascu, Dana L ^b   McDade, Eric M ^a   Ikonomovic, Snezana ^a   James, Jeffrey A ^a   Minhas, Davneet ^a   Mowrey, Wenzhu ^c   Sheu, Lei K ^a   Snitz, Beth E ^a   Weissfeld, Lisa ^d   Gianaros, Peter J ^a   Aizenstein, Howard J ^a   Price, Julie C ^a   Mathis, Chester A ^a   Lopez, Oscar L ^a   Klunk, William E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d University of Iowa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; PRESENILIN 1; PRESENILIN 2; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; BIOLOGICAL MARKER; THIAZOLE DERIVATIVE;

ADULT; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BRAIN SIZE; CLINICAL FEATURE; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; FEMALE; GENE MUTATION; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLISM; MINI MENTAL STATE EXAMINATION; MUTATIONAL ANALYSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECALL; REGISTER; VERBAL MEMORY; WORD LIST RECALL; AGED; BRAIN CORTEX; DISEASE COURSE; GENETICS; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOIDOSIS; ANILINE COMPOUNDS; BIOMARKERS; CEREBRAL CORTEX; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THIAZOLES;

EID: 84937515117     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00135-0     Document Type: Article

References (35)

1. 2014 Alzheimer's disease facts and figures. Alzheimers Dement 2014, 10:e47-e92. Alzheimer's Association.
2. Sperling RA, Jack CR, Aisen PS Testing the right target and right drug at the right stage. Sci Transl Med 2011, 3:111cm33.
3. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804.
4. Benzinger TLS, Blazey T, Jack CR, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci USA 2013, 110:E4502-E4509.
5. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013, 12:357-367.
6. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
7. Fleisher AS, Chen K, Quiroz YT, et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant alzheimer disease kindred: a cross-sectional study. JAMA Neurol 2015, 72:316-324.
8. Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014, 6:226ra30.
9. Sperling RA, Karlawish J, Johnson KA Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 2013, 9:54-58.
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
11. Diagnostic and statistical manual of mental disorders 1995, American Psychiatric Association, American Psychiatric Publishing, Arlington. 4th edn.
12. Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology 2000, 55:1854-1862.
13. Nebes RD, Snitz BE, Cohen AD, et al. Cognitive aging in persons with minimal amyloid-beta and white matter hyperintensities. Neuropsychologia 2013, 51:2202-2209.
14. Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012, 71:765-775.
15. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007, 27:6174-6184.
16. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994, 44:609-614.
17. Folstein MF, Folstein SE, McHugh PR 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
18. Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993, 43:2412-2414.
19. Patenaude B, Smith SM, Kennedy DN, Jenkinson M A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 2011, 56:907-922.
20. Pfefferbaum A, Rohlfing T, Rosenbloom MJ, Sullivan EV Combining atlas-based parcellation of regional brain data acquired across scanners at 1.5 T and 3.0 T field strengths. Neuroimage 2012, 60:940-951.
21. Jack CR, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997, 49:786-794.
22. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-319.
23. Cohen AD, Price JC, Weissfeld LA, et al. Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: an example of brain reserve. J Neurosci 2009, 29:14770-14778.
24. Cohen AD, Mowrey W, Weissfeld LA, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage 2013, 71:207-215.
25. Pedan A Smoothing with SAS Proc Mixed. Seattle SAS Users Group International Proceedings. March, 2003. Paper 26828 (accessed Sept 8, 2014). http://www2.sas.com/proceedings/sugi28/268-28.pdf.
26. Jack CR, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011, 68:1526-1535.
27. Jack CR, Holtzman DM Biomarker modeling of Alzheimer's disease. Neuron 2013, 80:1347-1358.
28. Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 2006, 47:1778-1786.
29. Villemagne VL, Ataka S, Mizuno T, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 2009, 66:1537-1544.
30. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
31. Fleisher AS, Chen K, Quiroz YT, et al. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol 2012, 11:1057-1065.
32. Caroli A, Frisoni GB The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging 2010, 31:1263-1274.
33. Jack CR, Wiste HJ, Lesnick TG, et al. Brain β-amyloid load approaches a plateau. Neurology 2013, 80:890-896.
34. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006, 5:828-834.
35. Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014, 83:253-260.